Plasmodium vivax antigen (PvAg)

Plasmodium vivax antigens represent a diverse collection of proteins expressed by the P. vivax parasite throughout its complex life cycle, playing pivotal roles in its survival and pathogenesis. Key antigens such as the Circumsporozoite Protein (CSP) and the Duffy Binding Protein (DBP) are essential for host-parasite interactions, facilitating the recognition of hepatocytes and the invasion of reticulocytes by binding to the host's Duffy Antigen Receptor for Chemokines (DARC) [1, 14, 19]. These proteins are primary targets for the development of vaccines and rapid diagnostic tests (RDTs), which use antibodies to capture specific biomarkers like parasite lactate dehydrogenase (pLDH) and aldolase [7, 11]. Therapeutic efforts mainly involve vaccine candidates, such as VMP001 and various PvDBP formulations, which aim to induce neutralizing antibodies that block the parasite's entry into human cells [1, 15]. However, the therapeutic utility of these antigens is significantly hindered by high genetic polymorphism and the parasite's ability to remain dormant as hypnozoites, which are often immunologically silent [5, 6, 13]. Consequently, existing interventions often provide only partial, strain-specific protection rather than broad sterile immunity [8, 10].

Other names

P. vivax antigensVivax malaria antigensPlasmodium vivax surface proteinsPvAgPvCSP (Circumsporozoite protein)PvDBP (Duffy binding protein)PvMSP1 (Merozoite surface protein 1)PvAMA1 (Apical membrane antigen 1)PvRBP (Reticulocyte binding protein)PvTRAgs (Tryptophan-rich antigens)PvLDH (Plasmodium lactate dehydrogenase)PvAldolase

Vaccines targeting these antigens induce the production of neutralizing antibodies that interfere with the parasite's ability to bind to and invade host hepatocytes or reticulocytes, effectively halting progression and transmission of the malaria parasite.